Immunology and Bi...
Follow
Find
7.5K views | +4 today
 
Scooped by Gilbert Faure au nom de l'ASSIM
onto Immunology and Biotherapies
Scoop.it!

MMRGlobal Receives Cancer-Fighting Anti-CD20 Monoclonal Antibodies Patent ... - MENAFN.COM

MMRGlobal Receives Cancer-Fighting Anti-CD20 Monoclonal Antibodies Patent ...
MENAFN.COM
This is thefourth country to issue this patent as a result of the ExpeditedPatent Allowance Program which follows the issuance of U.S.
more...
No comment yet.
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert Faure au nom de l'ASSIM's insight:

We choose Scoop.it as the best curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Immuno-Oncology - Merck Serono

Immuno-Oncology - Merck Serono | Immunology and Biotherapies | Scoop.it
PipelineThe current immuno-oncology portfolio comprises therapeutic candidates in early clinical development and a pipeline of preclinical molecules. Lead investigational candidates in clinical development include:avelumab** (MSB0010718C) 
Avelumab (also known as MSB0010718C) is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody. By inhibiting PD-L1 interactions, avelumab is thought to enable the activation of T-cells and the adaptive immune system. By retaining a native Fc-region, avelumab is thought to engage the innate immune system and could induce antibody-dependent cell-mediated cytotoxicity (ADCC).**avelumab = proposed International Non-proprietary Name (INN), formerly referred to as Anti-PD-L1 mAb (MSB0010718C)NHS-IL12 
NHS-IL12 (also known as MSB0010360) is an investigational cancer immunotherapy (immunocytokine) that is designed to target interleukin-12 to necrotic regions found in solid tumors. 

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Findings suggest development of 'post-infection' vaccine to reduce TB rates in ... - News-Medical.net

Findings suggest development of 'post-infection' vaccine to reduce TB rates in ... - News-Medical.net | Immunology and Biotherapies | Scoop.it
A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

GEN | Insight & Intelligence™:AACR Special: Serial Killer Cells on the Side of the Angels

GEN | Insight & Intelligence™:AACR Special: Serial Killer Cells on the Side of the Angels | Immunology and Biotherapies | Scoop.it
At the annual meeting of the American Association of Cancer Researchers, presenters discuss strategies to improve the safety and effectiveness of reengineered T cells in eradicating tumors.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, April 23, 1:58 AM

CAR T Cell immunotherapy, TIL, ATC, TCR   unpredictable toxicity at AACR 2015

Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

HIV Immunotherapy Promising in First Human Study - NIH Research Matters - National Institutes of Health (NIH)

HIV Immunotherapy Promising in First Human Study - NIH Research Matters - National Institutes of Health (NIH) | Immunology and Biotherapies | Scoop.it
An experimental antibody significantly reduced HIV levels in infected people for as long as 28 days. The approach might help to combat a wide range of HIV strains.

 

In the current study, the researchers evaluated one of these promising monoclonal anti-HIV antibodies in people. The small phase 1 clinical trial included 29 volunteers—17 HIV-infected and 12 uninfected. The study was supported by the Bill and Melinda Gates Foundation, NIH’s National Institute of Allergy and Infectious Diseases (NIAID), and others. Results appeared online on April 8, 2015, in Nature.

 

The participants received a single intravenous dose (of 1, 3, 10, or 30 milligrams per kilogram of body weight) of the experimental antibody called 3BNC117. The antibody was well-tolerated by all participants. Among those infected with HIV, the 2 lower doses caused small and transient changes in blood HIV levels. The 8 participants who received the highest dose, however, had significant and rapid decreases in HIV. The virus’s resistance to the antibody was variable. In some people, HIV remained sensitive to 3BNC117 for 28 days.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, April 25, 3:20 AM

NIH  

 

 Dr. Michel C. Nussenzweig of the Howard Hughes Medical Institute at Rockefeller University 

 

At a GlanceA single infusion of an experimental antibody significantly reduced HIV levels in infected people for as long as 28 days.This and similar antibodies might help to combat a wide range of HIV strains.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Precision Immunology: The Promise of Immunotherapy for the Treatment of Cancer

Precision Immunology: The Promise of Immunotherapy for the Treatment of Cancer | Immunology and Biotherapies | Scoop.it
"Precision Immunology: The Promise of Immunotherapy for the Treatment of Cancer [EDITORIALS]" JCO http://t.co/scQQMzSmF6
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Adaptimmune - engineered, increased affinity T cell receptors

Adaptimmune - engineered, increased affinity T cell receptors | Immunology and Biotherapies | Scoop.it
Adaptimmune - increased affinity T cell receptors . Adaptimmune is focused on T cells to target and destroy cancer by using increased affinity TCRs .
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Humanized anti-CD25 monoclonal antibody treatment of steroid-refractory acute ... - Nature.com

Humanized anti-CD25 monoclonal antibody treatment of steroid-refractory acute ...
Nature.com
The anti-CD25 monoclonal antibody (mAb) is one of the most used second-line treatment choices for steroid-refractory aGVHD.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Comprehensive two-dimensional liquid chromatography of therapeutic monoclonal antibody digests - Springer

Comprehensive two-dimensional liquid chromatography of therapeutic monoclonal antibody digests - Springer | Immunology and Biotherapies | Scoop.it
Comprehensive two-dimensional liquid chromatography of therapeutic monoclonal antibody digests #mAbs #biosimilars #LC
http://t.co/7liwH8lPP0
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Comprehensive Sequence and Post-Translational Modifications Analysis of Monoclonal Antibody by Flash Digest and LC-High Resolution MS>

Comprehensive Sequence and Post-Translational Modifications Analysis of Monoclonal Antibody by Flash Digest and LC-High Resolution MS> | Immunology and Biotherapies | Scoop.it
Search for application articles, scientific posters, methods, techniques and case studies for your laboratory science application on SelectScience.net.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

AnaptysBio announces advancement of anti-IL-36R antibody for treatment of ... - Healio

AnaptysBio announces advancement of anti-IL-36R antibody for treatment of ... - Healio | Immunology and Biotherapies | Scoop.it
AnaptysBio recently announced the advancement of its anti-interleukin-36 receptor antibody into investigational new drug-enabling studies as a novel treatment for generalized pustular psoriasis.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Re-engineering lupus into a cancer killer

Re-engineering lupus into a cancer killer | Immunology and Biotherapies | Scoop.it
Researchers have devised a way to re-engineer lupus antibodies to turn them into potential cancer killers. Lupus is a chronic inflammatory disease that occurs when the immune system attacks its own organs, tissues, or joints.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Immunology and Cell Biology - Boosting regulato...

Immunology and Cell Biology - Boosting regulato... | Immunology and Biotherapies | Scoop.it
the current article by Helling et al.12 supports the clinical use of CD4-mediated manipulation of Tregs for tolerance induction in patients with autoimmune disease or with graft-versus-host disease.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody

Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody | Immunology and Biotherapies | Scoop.it
Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody. . .

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, April 27, 10:21 AM
Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody PreviewView full textDownload full textSupplementalAccess optionsDOI:10.1080/19420862.2015.1032491Sanjaya Singha*, Rachel R. Kroe-Barretta, Keith A. Canadaa, Xiang Zhua, Eliud Sepulvedaa, Helen Wua, Yaqin Hea, Ernest L Raymondb, Jennifer Ahlberga, Lee E. Fregoa, Laura M Amodeoa, Katrina M Catrona, David H. Preskya & Jeffrey H. Hankec Publishing models and article dates explainedReceived: 20 Jan 2015Accepted: 18 Mar 2015
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Anti-Semaphorin 3A neutralization monoclonal antibody prevents sepsis development in lipopolysaccharide-treated mice

Anti-Semaphorin 3A neutralization monoclonal antibody prevents sepsis development in lipopolysaccharide-treated mice | Immunology and Biotherapies | Scoop.it
Anti-Semaphorin 3A neutralization monoclonal antibody prevents sepsis development in lipopolysaccharide-treated mice http://t.co/QPf5GqdpK1
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Meditope Biosciences

Meditope Biosciences | Immunology and Biotherapies | Scoop.it

PASADENA, Calif., April 20, 2015 /PRNewswire/ -- Meditope Biosciences, Inc., a biotechnology company developing novel antibody-based products using its proprietary technology, today announced presentation of data demonstrating the use of its SnAP technology platform for the development of antibody-drug conjugates (ADCs). The data were presented in an abstract at the AACR Annual Meeting 2015, taking place April 18-22 in Philadelphia.

 

Scientists at the company demonstrated the successful transplantation of the meditope binding site to several antibodies. Meditope-peptides of different affinities were then selected by rational design and fine-tuned according to the requirements of specific application. For ADC development, data show that the meditope-peptides are conjugated with cytotoxic payloads and the higher the affinity of the meditope-peptide-drug conjugate for the antibody, the higher the complex's cytotoxic potential against antigen-positive tumor cells.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, April 21, 7:56 AM

Meditope Biosciences' SnAP - Site-specific, novel Antibody Platform—technology is carving a new space in antibody design by turning antibodies into a "Lego-like" piece that can be combined with other pieces to expand functionality by easily 'snapping' anything imaginable on to (or off of) an antibody.

Scooped by Gilbert Faure au nom de l'ASSIM from Melanoma BRAF Inhibitors Review
Scoop.it!

Therapeutic Advances and Treatment Options in Metastatic Melanoma

Therapeutic Advances and Treatment Options in Metastatic Melanoma | Immunology and Biotherapies | Scoop.it
This review discusses the development of targeted and immune therapies for advanced melanoma, reviews current patient management, and highlights future directions.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, April 25, 3:37 AM
Review | April 23, 2015Therapeutic Advances and Treatment Options in Metastatic Melanoma FREE ONLINE FIRSTDouglas B. Johnson, MD, MSCI1,2; Jeffrey A. Sosman, MD1,2[+] Author AffiliationsJAMA Oncol. Published online April 23, 2015. doi:10.1001/jamaoncol.2015.0565
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases, Immunotherapy, Future Medicine

Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases, Immunotherapy, Future Medicine | Immunology and Biotherapies | Scoop.it
Progress monoclonal antibody #biosimilars development: #infliximab #biosimilar CT-P13 in treatment rheumatic diseases
http://t.co/JlBWYQ61Nd
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

T-cell therapy sends young cancer patients into remission

T-cell therapy sends young cancer patients into remission | Immunology and Biotherapies | Scoop.it
More than 90 percent of children and young adults with acute lymphoblastic leukemia, or ALL, are in remission after treatment as part of a promising Seattle Children’s clinical trial, researchers reported.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Novel approach allows real-time imaging of ongoing immune response

Novel approach allows real-time imaging of ongoing immune response | Immunology and Biotherapies | Scoop.it
A novel approach that allows real-time imaging of the immune system's response to the presence of tumors—without the need for blood draws or invasive biopsies—offers a potential breakthrough both in diagnostics and in the ability to monitor...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Opinion: Predicting the Efficacy of Cancer Immunotherapy - The Scientist (press release) (registration)

Opinion: Predicting the Efficacy of Cancer Immunotherapy - The Scientist (press release) (registration) | Immunology and Biotherapies | Scoop.it
T-cell receptor repertoires could help researchers determine whether a certain treatment will work for a given cancer patient. 
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Breakthrough development in cancer immunology published in Nature

Breakthrough development in cancer immunology published in Nature | Immunology and Biotherapies | Scoop.it
BioNTech AG announced the publication of a scientific article on therapeutic immune responses to cancer in the internationally renowned scientific journal Nature.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

PLOS Pathogens: The Ebola Epidemic Crystallizes the Potential of Passive Antibody Therapy for Infectious Diseases

PLOS Pathogens: The Ebola Epidemic Crystallizes the Potential of Passive Antibody Therapy for Infectious Diseases | Immunology and Biotherapies | Scoop.it

The current Ebola epidemic provides a dramatic example of the potential of passive antibody therapy for infectious diseases that is also instructive of the hurdles and limitations involved in wide-scale reintroduction of this powerful anti-infective strategy. Passive antibody therapy was first used in the 1890s as "serum therapy" and was the first effective anti-infective therapy. Serum therapy was largely discontinued with the advent of antibiotic therapy in the early 1940s because it could not compete with regards to cost or ease of administration and had additional complexities, including that it had to be administered early in disease, it manifested lot-to-lot variation, and its efficacy required immune donors and the availability of a specific microbiological diagnosis so sera could be matched to the disease-causing microorganism [1]. Serum therapy using heterologous sera was also associated with "serum sickness," a syndrome caused by the formation of antigen-antibody complexes. However, antibiotic therapy was never shown to be superior in efficacy to antibody therapy and there were some conditions, such as pneumococcal pneumonia, where it may have had some advantages. Despite their wholesale abandonment, antibody therapies did retain a niche for certain conditions where no drugs were available, such as the prevention and/or treatment of tetanus, botulism, and certain viral diseases. The development of hybridoma technology and monoclonal antibodies (mAbs) in the mid-1970s promised to solve many of the problems of serum therapy, but, to date, there has not been formal reintroduction of antibody therapies for infectious diseases despite considerable and ongoing efforts to develop such therapies against viral diseases, such as HIV infection, and bacterial diseases, such as those caused byPseudomonas aeruginosa and Staphylacoccous aureus. In contrast, mAbs have revolutionized the treatment of many cancers and rheumatic diseases and dozens have been licensed. Here we analyze why Ab-based therapies remain so underdeveloped for infectious diseases through the prism of the Ebola epidemic.


Via Ed Rybicki, Krishan Maggon
more...
Krishan Maggon 's curator insight, April 24, 7:15 AM

Citation: Casadevall A, Pirofski L-a (2015) The Ebola Epidemic Crystallizes the Potential of Passive Antibody Therapy for Infectious Diseases. PLoS Pathog 11(4): e1004717. doi:10.1371/journal.ppat.1004717

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Study finds increasing size of elderly population as major contributor to TB infection in China

Study finds increasing size of elderly population as major contributor to TB infection in China | Immunology and Biotherapies | Scoop.it
A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Experimental Anti-Cholesterol Drug Shows Promise | Medical Observer

Experimental Anti-Cholesterol Drug Shows Promise | Medical Observer | Immunology and Biotherapies | Scoop.it
"Evolocumab works differently than traditional statins. It is a human monoclonal antibody that blocks a har..." http://t.co/VuuAI6pfXZ
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

MaxCyte mRNA-CAR

MaxCyte mRNA-CAR | Immunology and Biotherapies | Scoop.it
The MaxCyte GT® Flow Transfection System is a universal platform technology for rapid, automated loading of CAR (chimeric antigen receptor) mRNA into peripheral blood mononuclear cells using closed-system aseptic processing.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, April 22, 2:17 AM

Press Release:: MaxCyte and Johns Hopkins University Announce Strategic Immuno-Oncology Collaboration to Advance CAR T-cell Therapies